These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1960 related articles for article (PubMed ID: 8486420)

  • 1. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
    Boon T
    Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
    [No Abstract]   [Full Text] [Related]  

  • 2. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes.
    Coulie P; Weynants P; Muller C; Lehmann F; Herman J; Baurain JF; Boon T
    Ann N Y Acad Sci; 1993 Aug; 690():113-9. PubMed ID: 8368730
    [No Abstract]   [Full Text] [Related]  

  • 3. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
    Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
    Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
    [No Abstract]   [Full Text] [Related]  

  • 4. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 5. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
    Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
    Dermatology; 1993; 186(4):278-80. PubMed ID: 8513199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy with MAGE antigens.
    Coulie PG
    Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
    [No Abstract]   [Full Text] [Related]  

  • 7. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
    Van den Eynde B; Peeters O; De Backer O; Gaugler B; Lucas S; Boon T
    J Exp Med; 1995 Sep; 182(3):689-98. PubMed ID: 7544395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination?
    Coulie PG
    Stem Cells; 1995 Jul; 13(4):393-403. PubMed ID: 7549898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rejection antigens of tumors and specific immunotherapy of cancer].
    Boon T; Lucas S
    Bull Mem Acad R Med Belg; 1996; 151(12):469-79. PubMed ID: 9491625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.
    De Smet C; Lurquin C; De Plaen E; Brasseur F; Zarour H; De Backer O; Coulie PG; Boon T
    Eye (Lond); 1997; 11 ( Pt 2)():243-8. PubMed ID: 9349420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
    van der Bruggen P; Traversari C; Chomez P; Lurquin C; De Plaen E; Van den Eynde B; Knuth A; Boon T
    Science; 1991 Dec; 254(5038):1643-7. PubMed ID: 1840703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
    Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
    Hoon DS; Morisaki T; Uchiyama A; Hayashi Y; Foshag LJ; Nizze AJ; Morton DL
    Ann N Y Acad Sci; 1993 Aug; 690():343-5. PubMed ID: 8368751
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Kirkin AF; Dzhandzhugazyan K; Zeuthen J
    Exp Clin Immunogenet; 1998; 15(1):19-32. PubMed ID: 9619397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with VMO for melanoma.
    Wallack MK; Sivanandham M
    Ann N Y Acad Sci; 1993 Aug; 690():178-89. PubMed ID: 8368736
    [No Abstract]   [Full Text] [Related]  

  • 18. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
    Coulie PG; Lehmann F; Lethé B; Herman J; Lurquin C; Andrawiss M; Boon T
    Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7976-80. PubMed ID: 7644523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tumor-regression antigens in melanoma.
    Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
    Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining tumor antigens: mRNA, protein or cytotoxicity?
    Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
    Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 98.